Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Rituximab (Rituxan) - anti CD 20 monoclonal antibody
Rituximab for the treatment of multiple sclerosis: a review | SpringerLink
Figure 1 from Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus? | Semantic Scholar
B-lymphocyte Antigen CD20 Epitope Peptide Fragment, Bound To Rituximab (Fab Fragment). Indications for Rituximab Include Leukemia Stock Illustration - Illustration of autoimmune, pdb2osl: 188464521
An analysis of Rituximab dose reduction & CD 19 monitoring
Rituximab in nephrology
Rituximab therapy in autoimmune pulmonary alveolar proteinosis | European Respiratory Society
anti-CD20 (Rituximab) - ACE Biolabs Antibody │ Chemical │ Enzyme
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab | Science
Rituximab - Altmeyers Encyclopedia - Department Internal medicine
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Far- and near-UV CD spectra of (a) Rituximab and (b) Etanercept... | Download Scientific Diagram
Rituximab - Wikipedia
Efficacy and Toxicity of Rituximab in Multiple Sclerosis | Archives of Neuroscience | Full Text
Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies | Revista Iberoamericana de Micología
Higher order structure analyzed by CD, FT-IR and DSC for CT-P10,... | Download Scientific Diagram
Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20 | Cell Death & Disease
Drug Repurposing for CD - CDCN
John Libbey Eurotext - Hématologie - Loss of CD20 expression on CLL cells following treatment with rituximab
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial - The Lancet Rheumatology
Frontiers | Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
Anti-CD20 Antibody Therapy for B-Cell Lymphomas | NEJM
Frontiers | A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
B-lymphocyte Antigen CD20 Epitope Peptide Fragment, Bound To Rituximab (Fab Fragment). Indications for Rituximab Include Leukemia Stock Illustration - Illustration of arthritis, pemphigus: 188464555
Rituximab | Offarm
Rituximab Monitoring
